Antenatal Allopurinol During Fetal Hypoxia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00189007

Recruitment Status : Unknown

Verified March 2012 by dr. M.J.N.L. Benders, UMC Utrecht.
Recruitment status was: Active, not recruiting

First Posted : September 16, 2005

Last Update Posted : March 29, 2012

Sponsor:

Collaborator:

ZonMw: The Netherlands Organisation for Health Research and Development

Information provided by (Responsible Party):

dr. M.J.N.L. Benders, UMC Utrecht

Study Description

Brief Summary:

A former study (submitted) in 32 severely asphyxiated infants participating in a randomized double blind study, in which early postnatal allopurinol or a placebo (within 4 hours after birth) was administered to reduce free radical formation and consequently reperfusion/reoxygenation injury to the newborn brain, showed an unaltered high mortality and no clinically relevant improvement in morbidity in infants treated with allopurinol. It was hypothesized that postnatal allopurinol treatment started too late to reduce reperfusion-induced free radical surge and that initiating allopurinol treatment of the fetus with (imminent) hypoxia already via the mother during labor will be more effective to reduce free radical-induced post-asphyxial brain damage.

Condition or disease	Intervention/treatment	Phase
Fetal Hypoxia Reperfusion Injury	Drug: Allopurinol sodium Drug: Mannitol	Phase 3

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	222 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	Does Antenatal Allopurinol Administration Reduce Post-hypoxic-ischemic Reperfusion Damage During Fetal Hypoxia in the Newborn?
Study Start Date :	October 2009
Actual Primary Completion Date :	December 2011
Estimated Study Completion Date :	December 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Mannitol Allopurinol Allopurinol sodium

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Allopurinol 500 mg allopurinol/ 50 mL water for injection intravenously	Drug: Allopurinol sodium Allopurinol sodium 500 mg / 50 mL, intravenously, single dose Other Name: Acepurin
Placebo Comparator: Placebo 500 mg mannitol/50 mL water for injection intravenously	Drug: Mannitol Mannitol 500 mg/50 mL water for injection, intravenously, single dose

Outcome Measures

Primary Outcome Measures :

Free radical production and markers of neuronal damage [ Time Frame: Up to 24 hours postpartum ]

Secondary Outcome Measures :

Developmental outcome [ Time Frame: Up to 5 years of age ]
Mortality [ Time Frame: Up to 28 days postpartum ]
Severe composite morbidity [ Time Frame: Up to 28 days postpartum ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Gestational age of 36 weeks or more
Non-reassuring CTG, significant events on the STAN-monitor AND/OR FBS < 7.20

Exclusion Criteria:

Chromosomal abnormalities

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189007

Locations

Layout table for location information

Netherlands
AMC
Amsterdam, Netherlands
VUmc
Amsterdam, Netherlands
Gelre hospitals
Apeldoorn, Netherlands
Jeroen Bosch Hospital
Den Bosch, Netherlands
Groene Hart Hospital
Gouda, Netherlands
UMCG
Groningen, Netherlands
LUMC
Leiden, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Wilhelmina Children's Hospital/UMC Utrecht
Utrecht, Netherlands, 3508AB
Diakonessenhuis
Utrecht, Netherlands
Maxima Medical Center
Veldhoven, Netherlands

Sponsors and Collaborators

UMC Utrecht

ZonMw: The Netherlands Organisation for Health Research and Development

Investigators

Layout table for investigator information

Study Director:	Frank van Bel, Prof MD PhD	Wilhelmina Children's Hospital/UMC Utrecht
Principal Investigator:	Manon JN Benders, MD, PhD	UMC Utrecht
Principal Investigator:	Jan B Derks, MD, PhD	UMC Utrecht
Principal Investigator:	Joepe J Kaandorp, MD	UMC Utrecht
Principal Investigator:	Gerard H Visser, MD, PhD	UMC Utrecht
Principal Investigator:	Ben WJ Mol, MD, PhD	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Principal Investigator:	Carin MA Rademaker, PhD	Clinical Pharmacy, UMCU

More Information

Publications:

Kaandorp JJ, Benders MJ, Rademaker CM, Torrance HL, Oudijk MA, de Haan TR, Bloemenkamp KW, Rijken M, van Pampus MG, Bos AF, Porath MM, Oetomo SB, Willekes C, Gavilanes AW, Wouters MG, van Elburg RM, Huisjes AJ, Bakker SC, van Meir CA, von Lindern J, Boon J, de Boer IP, Rijnders RJ, Jacobs CJ, Uiterwaal CS, Mol BW, Visser GH, van Bel F, Derks JB. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study. BMC Pregnancy Childbirth. 2010 Feb 18;10:8. doi: 10.1186/1471-2393-10-8.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Klumper J, Kaandorp JJ, Schuit E, Groenendaal F, Koopman-Esseboom C, Mulder EJH, Van Bel F, Benders MJNL, Mol BWJ, van Elburg RM, Bos AF, Derks JB; ALLO-trial study group. Behavioral and neurodevelopmental outcome of children after maternal allopurinol administration during suspected fetal hypoxia: 5-year follow up of the ALLO-trial. PLoS One. 2018 Aug 23;13(8):e0201063. doi: 10.1371/journal.pone.0201063. eCollection 2018.

Kaandorp JJ, Benders MJ, Schuit E, Rademaker CM, Oudijk MA, Porath MM, Oetomo SB, Wouters MG, van Elburg RM, Franssen MT, Bos AF, de Haan TR, Boon J, de Boer IP, Rijnders RJ, Jacobs CJ, Scheepers LH, Gavilanes DA, Bloemenkamp KW, Rijken M, van Meir CA, von Lindern JS, Huisjes AJ, Bakker SC, Mol BW, Visser GH, Van Bel F, Derks JB. Maternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed. 2015 May;100(3):F216-23. doi: 10.1136/archdischild-2014-306769. Epub 2014 Dec 15.

Kaandorp JJ, van den Broek MP, Benders MJ, Oudijk MA, Porath MM, Bambang Oetomo S, Wouters MG, van Elburg R, Franssen MT, Bos AF, Mol BW, Visser GH, van Bel F, Rademaker CM, Derks JB; ALLO-trial Study Group. Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour. Arch Dis Child Fetal Neonatal Ed. 2014 Mar;99(2):F144-8. doi: 10.1136/archdischild-2013-304876. Epub 2013 Dec 18.

Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, Longini M, Buonocore G, Venegas M, Baquero H, Visser GH, Van Bel F. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009 Jul;124(1):350-7. doi: 10.1542/peds.2008-2228.

Layout table for additonal information

Responsible Party:	dr. M.J.N.L. Benders, MD, PhD, UMC Utrecht
ClinicalTrials.gov Identifier:	NCT00189007
Other Study ID Numbers:	ZonMw 170991001 ALLO-trial ( Other Identifier: Dutch Consortium for Studies in Obstetrics and Gynaecology ) 2006-005796-18 ( EudraCT Number ) 170991001 ( Other Grant/Funding Number: ZonMw ) NTR-1383 ( Registry Identifier: Dutch Trial Register ) NL26516.000.09 ( Other Identifier: The Central Committee on Research Involving Human Subjects (CCMO) )
First Posted:	September 16, 2005 Key Record Dates
Last Update Posted:	March 29, 2012
Last Verified:	March 2012

Keywords provided by dr. M.J.N.L. Benders, UMC Utrecht:


allopurinol neuroprotection reperfusion injury fetal hypoxia post hypoxic-ischemic reperfusion damage

Additional relevant MeSH terms:

Layout table for MeSH terms

Fetal Hypoxia Reperfusion Injury Hypoxia Signs and Symptoms, Respiratory Vascular Diseases Cardiovascular Diseases Postoperative Complications Pathologic Processes Fetal Diseases Pregnancy Complications Allopurinol Mannitol	Antimetabolites Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Gout Suppressants Antirheumatic Agents Free Radical Scavengers Antioxidants Protective Agents Physiological Effects of Drugs Diuretics, Osmotic Diuretics Natriuretic Agents

To Top